Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel

Koichi Uemura1,5†, Yasuhide Miyoshi1,5*, Takashi Kawahara1, Jikuya Ryosuke1, Daisuke Yamashita1, Shuko Yoneyama1, Yumiko Yokomizo2, Kazuki Kobayashi3, Takeshi Kishida4, Masahiro Yao2 and Hiroji Uemura1

Abstract

Background: A computer-assisted diagnostic system for analyzing bone scans (BONENAVI) calculates the automated bone scan index (aBSI). Here we evaluated the aBSI as a prognostic imaging biomarker for men with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel.

Methods: We retrospectively analyzed 48 patients who received cabazitaxel for mCRPC and evaluated the ability of the aBSI to predict overall survival (OS). The Cox proportional hazards model was used to investigate the associations between baseline aBSI at cabazitaxel treatment and OS with the clinical variables as follows: age, number of cycles of docetaxel, serum prostate-specific antigen, hemoglobin (Hb), lactate dehydrogenase (LDH), and alkaline phosphatase. We determined the C-index to evaluate the discriminatory ability of our models when we included or excluded the aBSI from the analyses.

Results: The median OS after cabazitaxel treatment was 10.0 months, and patients with aBSI ≤1% achieved significantly longer OS compared with patients with aBSI ≥1%. Multivariate analysis showed that age, Hb, LDH, and aBSI were independent prognostic factors of OS. Adding aBSI to the base model increased the C-index from 0.78 to 0.80.

Conclusions: The aBSI may serve as a useful imaging biomarker for predicting OS among men with mCRPC treated with cabazitaxel. Prospective studies are required to establish the value of aBSI as prognostic imaging biomarker.

Keywords: Prostate cancer, Castration-resistant, Survival prediction, Bone scan index

Background

Although 80%–90% of prostate cancers with metastasis respond to initial hormone therapy, most patients finally develop to metastatic castration-resistant prostate cancer (mCRPC) [1, 2]. Sipuleucel-T, abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, and radium-223 have all improved survival among men with mCRPC and have been approved in western countries [3, 4].

Cabazitaxel is the first chemotherapeutic agent to prolong overall survival (OS) of patients with mCRPC who are administered docetaxel. A phase III randomized controlled clinical trial (TROPIC) found that cabazitaxel prolongs OS compared with mitoxantrone and reduces the relative risk of death by 30% [5]. Accordingly, cabazitaxel is widely used for patients with mCRPC. However, no clinical biomarkers are available for predicting survival.

A computer-assisted diagnostic system for analyzing bone scans (BONENAVI; Fujifilm RI Pharma Co. Ltd., Tokyo, Japan) calculates the automated bone scan index (aBSI) that provides an objective and quantitative evaluation of the burden imposed by bone metastasis [6]. The prognostic value of aBSI as a biomarker was evaluated for predicting the survival of men treated with life-prolonging agents such as enzalutamide [7], abiraterone [7, 8], docetaxel [9–11], and radium-223 [12]. Here we conducted a
retrospective analysis of the relationship between OS and baseline aBSI of patients with mCRPC treated with cabazitaxel.

Methods

Study design, patients, and treatment

We retrospectively analyzed 48 patients who were treated with cabazitaxel for bone-metastatic mCRPC between 2014 and 2016 at Yokohama City University Medical Center, Yokohama City University Hospital, and their associated hospitals. All patients had histologically confirmed prostate adenocarcinoma. The 2009 TNM clinical staging system and the 2005 International Society of Urologic Pathology Gleason grading system were used [13]. The clinical stages of all patients were evaluated using chest and body computed tomography as well as bone scans upon initiation of cabazitaxel treatment.

All patients were initially treated with androgen deprivation therapy (medical or surgical castration with an antiandrogen). After failure to CRPC, all patients were administered enzalutamide, abiraterone, or both, followed by docetaxel with dexamethasone, before cabazitaxel was administered. All patients received continuous androgen ablation therapy (an LH-RH analog) and oral dexamethasone (0.5–1.0 mg). Cabazitaxel treatment was continued until disease progression or unacceptable adverse events occurred.

Some patients received bisphosphonate or denosumab after the development of mCRPC. Patients were not administered sipuleucel-T and radium-223. For terminally ill patients, palliative therapy and pain control using morphine and palliative external beam radiotherapy were used as appropriate. Serum prostate-specific antigen (PSA) levels were measured using the Elecsys Total PSA Assay (Roche Diagnostics Corp., Basle, Switzerland).

Bone scan index

Bone scan images were obtained within 1 month before or after initiating cabazitaxel treatment and analyzed using
BONENAVI version 2 [14]. The automated method for analysis of anterior and posterior whole-body bone scan images was previously described [15]. The aBSI was calculated as the percentage of the sum of all hot-spots classified as bone metastases using the artificial neural network (ANN) values [14].

Statistical analysis
The Cox proportional hazards model with stepwise regression analysis was used to investigate the association between aBSI, OS, and clinical variables of patients treated with cabazitaxel as follows: age, number of cycles of docetaxel, serum PSA, hemoglobin (Hb), lactate dehydrogenase (LDH), and alkaline phosphatase (ALP). The cut-off values for age, number of cycles of docetaxel, serum PSA, Hb, LDH, and ALP were determined according to the median value of each variable. The cut-off value of aBSI was defined as 1.0% according to published studies [10, 15]. The relative risks and 95% confidence intervals (CIs) were calculated, and the C-index was used to assess the discriminatory ability of our models.

The Kaplan–Meier product-limit was used to estimate the survival distribution. The log-rank test was used for the analysis of survival differences. All statistical tests were two-sided, and the significance level was defined as alpha = 0.05. All analyses were conducted using IBM SPSS Statistics software for Windows, version 24 (IBM Corp., Armonk, NY, USA) and the R package (R Foundation for Statistical Computing, Vienna, Austria).

The experimental procedures were conducted in accord with the ethical standards of the Helsinki Declaration.

Table 2 Univariate analysis of predictions of overall survival of men with metastatic castration-resistant prostate cancer treated with cabazitaxel

| Predictor                      | HR  | 95% CI       | P value |
|-------------------------------|-----|--------------|---------|
| Age (≥71.2 years vs < 71.2)   | 2.6 | 1.1–6.0      | 0.023   |
| Number of cycles of docetaxel (≥10 cycles vs ≤9) | 0.8 | 0.4–1.7      | 0.533   |
| Baseline aBSI (≥1.0% vs < 1.0) | 3.1 | 1.1–9.2      | 0.036   |
| Baseline PSA (≥152.1 ng/mL vs < 152.1) | 1.7 | 0.7–3.7      | 0.218   |
| Baseline Hb (< 11.0 g/dL vs ≥11.0) | 3.6 | 1.6–8.1      | 0.002   |
| Baseline LDH (≥262 IU/L vs < 262) | 3.0 | 1.3–6.5      | 0.008   |
| Baseline ALP (≥414 IU/L vs < 414) | 2.0 | 0.9–4.5      | 0.100   |

* aBSI automated bone scan index, ALP alkaline phosphatase, Hb hemoglobin, LDH lactate dehydrogenase, PSA prostate-specific antigen
Table 3 Multivariate analysis of predictions of overall survival of men with metastatic castration-resistant prostate cancer treated with cabazitaxel

| Risk factors | HR (95% CI) | P value |
|--------------|-------------|---------|
| Age (≥71.2 years vs < 71.2) | 3.4 (1.3–9.1) | 0.013 |
| Number of cycles of docetaxel (≥10 cycles vs ≤9) | 0.8 (0.3–2.8) | 0.781 |
| Baseline aBSI (≥1.0% vs < 1.0) | 5.8 (1.1–30.3) | 0.031 |
| Baseline PSA (≥152.1 ng/mL vs < 152.1) | 0.8 (0.2–2.9) | 0.769 |
| Baseline Hb (< 11.0 g/dL vs ≥11.0) | 2.1 (1.0–6.2) | 0.034 |
| Baseline LDH (≥262 IU/L vs < 262) | 1.3 (0.8–2.1) | 0.014 |
| Baseline ALP (≥414 IU/L vs < 414) | 0.5 (0.2–1.6) | 0.255 |

aBSI automated bone scan index, ALP alkaline phosphatase, Hb hemoglobin, LDH lactate dehydrogenase, PSA prostate-specific antigen

Results

Patients’ characteristics are shown in Table 1. Among the 48 patients, the sites of metastasis were as follows: 13, only bone; 12, lymph node + bone; 3, visceral + bone; and 20, visceral + lymph node + bone. The median baseline PSA value was 152.1 ng/mL, and the median aBSI was 3.5% (range, 0.0%–12.9%). Twenty-five (56.2%) patients died, and all deaths were caused by prostate cancer.

The median OS of Kaplan–Meier initiated was 10.0 months (95%CI, 7.8–12.2) (Fig. 1). A Kaplan–Meier curve of OS after cabazitaxel treatment as a function of aBSI is shown in Fig. 2. The median OS of patients with aBSI < 1% (n = 17) and aBSI ≥1% (n = 31) was not reached and 7.8 months (95%CI: 4.6–10.9), respectively. Patients with aBSI < 1% had a significantly longer OS compared with patients with aBSI ≥1% (p = 0.027).

Univariate analysis revealed that age (hazard ratio [HR], 2.6; 95%CI, 1.1–6.0; p = 0.023), Hb (HR, 3.6; 95%CI, 1.6–8.1; p = 0.002), LDH (HR, 3.6; 95%CI, 1.3–6.5; p = 0.008), and aBSI (HR, 3.1; 95%CI, 1.1–9.2; p = 0.036) were prognostic factors for OS (Table 2). Multivariate analysis demonstrated that age (HR, 3.4; 95%CI, 1.3–9.1; p = 0.013), Hb (HR, 2.5; 95%CI, 1.1–6.2; p = 0.034), LDH (HR, 3.3; 95%CI, 1.3–8.6; p = 0.014), and aBSI (HR, 5.8; 95%CI, 1.1–30.3; p = 0.031) were independent prognostic factors of OS (Table 3).

We evaluated the discriminatory ability of our models by determining the C-index. The C-index in our model after cabazitaxel treatment was initiated was 0.80 for predicting OS, when aBSI was included was 0.80 for predicting OS.

Finally, we stratified the patients into cohorts at low risk (0–2 risk factor, n = 26) or high risk (3–4 risk factors, n = 22) (Table 4). There was a statistically significant difference in OS between these groups (p < 0.001) (Fig. 3).

Discussion

The aBSI is useful imaging biomarker for predicting the survival of men with prostate cancer, including those with hormone-naïve prostate cancer or mCRPC [6, 9, 11, 16–20]. For example, the survival of patients with mCRPC with aBSI ≥3% is shorter compared with men with aBSI < 3% who are treated with taxane-based chemotherapy [9]. Further, men with mCRPC with aBSI > 1% survive for shorter times compared with those with aBSI ≤1% who are treated with docetaxel [10]. Moreover, the aBSI is superior compared with the EOD score as a prognostic imaging biomarker [10].

Recent study demonstrated that not only baseline aBSI before treatment, but also aBSI change after treatment could be useful for prognostic imaging biomarker. Miyoshi et al. reported that decreased aBSI after abiraterone acetate or enzalutamide was an independent predictor for longer OS among men with mCRPC [7]. Reza et al. also reported that aBSI change after abiraterone acetate was related to survival time in mCRPC patients [8]. On the other hand, Fosbol et al. reported that aBSI was a prognostic biomarker for mCRPC patients received with Ra-223, although there was no significant association between aBSI change during Ra-223 therapy and OS [12].

Here we analyzed the association between OS, aBSI, and clinical variables of patients with mCRPC who were treated with cabazitaxel. We identified age, Hb, LDH, and PSA. aBSI was not included in the clinical profile. In our study, baseline aBSI ≥3% was an independent prognostic factor for predicting OS. baseline aBSI ≥3% was significantly associated with shorter survival in mCRPC patients treated with cabazitaxel.

Table 4 Distributions of the risk factors in the low and high risk groups

| Risk factors | Age ≥ 71.2 years | Hb < 11.0 g/dL | LDH ≥ 262 IU/L | aBSI ≥1.0% |
|--------------|-----------------|----------------|---------------|------------|
| Low risk     | Age ≥ 71.2 years | Hb < 11.0 g/dL | LDH ≥ 262 IU/L | aBSI ≥1.0% |
| (n = 26), n (%) | 8 (30.8) | 5 (19.2) | 6 (23.1) | 13 (50.0) |
| High risk    | Age ≥ 71.2 years | Hb < 11.0 g/dL | LDH ≥ 262 IU/L | aBSI ≥1.0% |
| (n = 22), n (%) | 16 (72.7) | 18 (81.8) | 18 (81.8) | 18 (81.8) |

aBSI automated bone scan index, Hb hemoglobin, LDH lactate dehydrogenase
and aBSI as independent prognostic factors of OS. Including the aBSI in the base model improved the C-index from 0.78 to 0.80. Therefore, the aBSI may serve as a promising imaging biomarker for predicting OS among men with mCRPC who are treated with cabazitaxel. Further, the aBSI may provide useful information about such patients.

Although we show here that the aBSI played an important role in evaluating bone metastases, our study has several limitations. For example, our study was retrospective, the number of subjects was small, and the observation periods were relatively short. Prospective evaluation of larger patient populations and longer observations are warranted to establish the usefulness of the aBSI as a prognostic imaging biomarker.

**Conclusion**

Our analyses strongly indicate that the aBSI may serve as a useful tool for risk stratification of patients with mCRPC undergoing treatment with cabazitaxel.

**Abbreviations**

aBSI: Automated bone scan index; ALP: Alkaline phosphatase; CI: Confidence interval; EOD: Extent of disease; Hb: Hemoglobin; HR: Hazard ratio; LDH: Lactate dehydrogenase; mCRPC: Metastatic castration-resistant prostate cancer; OS: Overall survival; PSA: Prostate-specific antigen

**Availability of data and materials**

All data used for this study are available from the corresponding author upon reasonable request.

**Authors’ contributions**

YM designed the study. YM and KU contributed to statistical analysis and wrote the manuscript. TK, JR, DY, SY, YY, KK, TK, HU, and MY supervised the study. All authors have read and approved the final manuscript.

**Ethics approval and consent to participate**

The Institutional Review Board of Yokohama City University Medical Center approved this study. Informed consent to participate in the study was obtained from the subjects.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

1. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997;15(1):382–8.
2. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998;160(4):1220–9.
3. Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J. New agents for prostate cancer. Ann Oncol. 2014;25(9):1700–9.
4. Sartor O, de Bono JS. Metastatic prostate Cancer. N Engl J Med. 2018;378(7):645–57.
5. de Bono JS, Oudard S, Ozgueroğlu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrog I, Mackenzie MJ, Shen L, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (London, England). 2010;376(9747):1147–54.
6. Hirokoshi H, Kikuchi A, Onoguchi M, Sjostrand K, Edenbrandt L. Computer-aided diagnosis system for bone scintigrams from Japanese patients: importance of training database. Ann Nucl Med. 2012;26(8):622–6.
7. Miyoshi Y, Uemura K, Kawahara T, Yoneyama S, Hattori Y, Teranishi JI, Ohta JI, Takebayashi S, Yokomizo Y, Hayashi N, et al. Prognostic value of automated bone scan index in men with metastatic castration-resistant prostate cancer treated with Enzalutamide or Abiraterone acetate. Clin Genitourin Cancer. 2017;15(4):472–8.
8. Reza M, Ohlsson M, Kaboteh R, Anand A, Franck-Lissbrant I, Damber JE, Widmark A, Thellenberg-Karlsson C, Budaus L, Steuber T, et al. Bone scan index as an imaging biomarker in metastatic castration-resistant prostate cancer: a multicentre study based on patients treated with Abiraterone acetate (Zytiga) in clinical practice. Eur Urol Focus. 2016;2(5):540–6.
9. Mitsui Y, Shiina H, Yamamoto Y, Hara moto M, Arichi N, Yasumoto H, Kitagaki H, Igawa M. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int. 2012;110(11 Pt B):E628–34.
10. Uemura K, Miyoshi Y, Kawahara T, Yoneyama S, Hattori Y, Teranishi J, Kondo K, Moriyama M, Takebayashi S, Yokomizo Y, et al. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer. BMC Cancer. 2016;16:109.
11. Kaboteh R, Gjertsson P, Leek H, Lomsmy M, Ohlsson M, Sjostrand K, Edenbrandt L. Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index. EJNMMI Res. 2013;3(1):64.
12. Fosbol MO, Petersen PM, Daugaard G, Holm S, Kjaer A, Mortensen J. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients. Ann Nucl Med. 2018;32(1):16–21.
13. Epstein JI, Allibro wn WC, Jr, Amin MB, Egevad LL, Committee IG. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228–42.
14. Koizumi M, Wagatsuru M, Miyaji N, Murata T, Miwa K, Takiguchi T, Makino T, Koyama M. Evaluation of a computer-assisted diagnosis system, BONENAVI version 2, for bone scintigraphy in cancer patients in a routine clinical setting. Ann Nucl Med. 2015;29(2):138–48.
15. Armstrong AJ, Kaboteh R, Carducci MA, Damber JE, Stadler WM, Hansen M, Edenbrandt L, Forsberg G, Nordle O, Pili R, et al. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urol Oncol. 2014;32(8):1308–16.
16. Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoeder H, Fox JJ, Heller G, Scher HI, Larson SM, Morris MJ. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012;30(5):519–24.
17. Poulsen MH, Rasmussen J, Ebeling RV, Schroll P, Gjertsson P, Ohlsson M, Sjostrand K, Edenbrandt L. Bone scan index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy. EJNMMI Res. 2013;3(1):9.
18. Poulsen MH, Rasmussen J, Ebeling RV, Schroll P, Gjertsson P, Ohlsson M, Sjostrand K, Edenbrandt L. Bone scan index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy. EJNMMI Res. 2013;3(1):9.
19. Kalderstam J, Sadik M, Edenbrandt L, Ohlsson M. Analysis of regional bone scan index measurements for the survival of patients with prostate cancer. BMC Med Imaging. 2014;14:24.
20. Poulsen MH, Rasmussen J, Ebeling RV, Schroll P, Gjertsson P, Ohlsson M, Sjostrand K, Edenbrandt L. Bone scan index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy. EJNMMI Res. 2013;3(1):9.